---
title: "JIUDIAN PHARMACEUTICAL: Expected revenue growth of 10% to 20% year-on-year for the fiscal year 2025"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/251835977.md"
description: "JIUDIAN PHARMACEUTICAL stated during an institutional research that the company's operating revenue for the fiscal year 2025 is expected to grow by 10% to 20% year-on-year, and the non-recurring net profit is also expected to grow by 10% to 20% year-on-year"
datetime: "2025-08-06T12:14:51.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/251835977.md)
  - [en](https://longbridge.com/en/news/251835977.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/251835977.md)
generator: "portal-rs"
---

# JIUDIAN PHARMACEUTICAL: Expected revenue growth of 10% to 20% year-on-year for the fiscal year 2025

JIUDIAN PHARMACEUTICAL stated during an institutional research that the company's operating revenue for the fiscal year 2025 is expected to grow by 10% to 20% year-on-year, and the non-recurring net profit is also expected to grow by 10% to 20% year-on-year

### Related Stocks

- [300705.CN](https://longbridge.com/en/quote/300705.CN.md)

## Related News & Research

- [Do Collagen Supplements Work? What the Research Actually Supports](https://longbridge.com/en/news/298593202.md)
- [TABLE-Asian physical rubber prices - September 10](https://longbridge.com/en/news/298555650.md)
- [Handa Oncology Receives FDA Final Approval for OMCAZIO(TM) (cabozantinib) Capsules](https://longbridge.com/en/news/298728074.md)
- [18:55 ETScholarshipOwl to Celebrate 3,000+ Scholarship Recipients at 1st 'Winners Bash'](https://longbridge.com/en/news/298373210.md)
- [Kelun-Biotech partner Windward Bio starts Phase 3 POLARIS-1 asthma trial of SKB378/WIN378](https://longbridge.com/en/news/298315933.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**